<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168816</url>
  </required_header>
  <id_info>
    <org_study_id>206209</org_study_id>
    <nct_id>NCT02168816</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis</brief_title>
  <acronym>CRO-OSTEO</acronym>
  <official_title>Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Infectious Diseases Society of America (IDSA) 2012 guidelines for the diagnosis and
      treatment of diabetic foot infections state that for the treatment of diabetic foot
      osteomyelitis &quot;No data support the superiority of any specific antibiotic agent or treatment
      strategy, route, or duration of therapy.&quot; Traditionally, osteomyelitis has been treated with
      a long course of intravenous antibiotics, generally six weeks. Oral antibiotics with high
      bioavailability and adequate bone penetration have been shown in published studies to be
      effective for the treatment of osteomyelitis.

      The investigators propose to conduct a prospective, single-center, randomized, open trial at
      Loyola University Medical Center (LUMC) comparing the efficacy of oral antibiotic therapy to
      intravenous (IV) antibiotic therapy for the treatment of diabetic foot osteomyelitis. The
      investigators hypothesize that oral antibiotic therapy is equivalent to IV antibiotic
      therapy.

      Bone/tissue cultures are obtained for all patients for clinical purposes and are sent to
      pathology for histologic examination and to the clinical microbiology laboratory for culture
      and susceptibility.

      Patients will receive six weeks of IV or oral antibiotic therapy depending upon their
      randomization group. Primary outcomes at six months clinical follow-up will include: (i) no
      evidence of bone infection and (ii) resolution of ulcer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently available literature is not adequate to determine the best agent, route, or
      duration of antibiotic therapy for the treatment of chronic osteomyelitis. The standard of
      therapy has been to treat patients with a parenteral antibiotic for four to six weeks. In a
      recent literature review by Spellberg et al. it was concluded that oral and parenteral
      antibiotic therapy have similar cure rates for the treatment of chronic osteomyelitis. Oral
      antibiotic therapy is associated with a lower risk to the patient due to avoiding the need of
      a central IV line. Additionally, oral therapy costs less than a course of IV antibiotics.
      Oral antibiotics with high bioavailability and good bone penetration include, fluoroquinoles,
      linezolid, trimethoprim/sulfamethoxazole (2 tabs bid), clindamycin and metronidazole. These
      antibiotics have been shown in recent studies to obtain levels in the bone that exceed MIC's
      of the targeted organisms.

      According to the IDSA 2012 guidelines for the treatment of diabetic foot infections, the
      diagnosis of osteomyelitis can be made via plain radiographs or MRI imaging (more sensitive).
      A bone scan can be considered if an MRI cannot be done. The preferred method of diagnosis is
      by bone culture and histology. The guidelines also recommend surgical debridement to healthy
      tissue for diabetic foot infections followed by antibiotic therapy.

      Study Aims

      The Purpose of this study is to compare the efficacy of oral antibiotic therapy with IV
      antibiotic therapy for the treatment of diabetic foot osteomyelitis following surgical
      debridement.

      Hypotheses: Oral Antibiotic Therapy is equivalent to IV Antibiotic Therapy for the Treatment
      of Diabetic Foot Osteomyelitis.

      Outcomes will be assessed at six months:

        1. No evidence of bone infection. (absence of infection based on clinical examination and
           down-trending of inflammatory markers)

        2. Resolution of ulcer will be measured as yes or no (binary variable)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Infection</measure>
    <time_frame>Six Months</time_frame>
    <description>No evidence of bone infection six months following completion of treatment, including (i) an absence of infection based on clinical examination and (ii) down-trending of inflammatory markers. This will be measured as yes or no (binary variable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of Ulcer</measure>
    <time_frame>Six Months</time_frame>
    <description>Resolution of ulcer will be measured as yes or no (binary variable)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Osteomyelitis</condition>
  <arm_group>
    <arm_group_label>Midfoot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with an infection on the midfoot are randomized to an oral therapy or an intravenous therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hindfoot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with an infection on the hindfoot are randomized to an oral therapy or an intravenous therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with an infection on the toe are randomized to an oral therapy or an intravenous therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin/tazobactam, cefepime, metronidazole, aztreonam,vancomycin, daptomycin, linezolid ,meropenem</intervention_name>
    <description>Individuals are not assigned to specific medications. Rather, individuals are only assigned to a route of therapy. Individuals assigned to intravenous therapy will receive an intravenous therapy as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.</description>
    <arm_group_label>Midfoot</arm_group_label>
    <arm_group_label>Hindfoot</arm_group_label>
    <arm_group_label>Toe</arm_group_label>
    <other_name>Piperacillin/tazobactam (Zosyn)</other_name>
    <other_name>Cefepime</other_name>
    <other_name>Metronidazole</other_name>
    <other_name>Aztreonam</other_name>
    <other_name>Vancomycin</other_name>
    <other_name>Daptomycin</other_name>
    <other_name>Linezolid (Zyvox)</other_name>
    <other_name>Meropenem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfamethoxazole/trimethoprim , clindamycin ,linezolid, moxifloxacin ,ciprofloxacin ,metronidazole</intervention_name>
    <description>Individuals are not assigned to specific medications. Rather, individuals are only assigned to a route of therapy. Individuals assigned to oral therapy will receive an oral therapy as determined by their primary healthcare provider. Individuals assigned to oral therapy will usually receive at least one of the following medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)</description>
    <arm_group_label>Midfoot</arm_group_label>
    <arm_group_label>Hindfoot</arm_group_label>
    <arm_group_label>Toe</arm_group_label>
    <other_name>Sulfamethoxazole/Trimethoprim (SMX-TMP)</other_name>
    <other_name>Clindamycin (Clindesse)</other_name>
    <other_name>Linezolid (Zyvox)</other_name>
    <other_name>Moxifloxacin (Avelox)</other_name>
    <other_name>Ciprofloxacin (Cetraxal)</other_name>
    <other_name>Metronidazole (Flagyl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  Diagnosis of Diabetes Mellitus (Per past medical history documented in the patient
             medical record)

          -  Foot osteomyelitis (distal to ankle)

          -  Bone biopsy with histologic evidence of acute or chronic inflammation

          -  Surgical debridement (in operating room)

        Exclusion Criteria:

          -  Absolute neutrophil count (ANC) &lt; 500

          -  Pregnant or lactating patients

          -  Patients with organisms resistant to oral therapy

          -  Internal hardware

          -  Definitive amputations (BKA)

          -  Limb ischemia (absent pedal pulses or ABI &lt; 0.5)

          -  Bone biopsy histology negative for inflammation

          -  Negative bone/tissue cultures and no evidence of infection demonstrated on microscopic
             examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Pinzur, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie Labuszewski, Pharm.D.</last_name>
    <phone>708-216-2307</phone>
    <email>llabuszewski@lumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tammy Rhoda, MPH</last_name>
    <phone>708-216-5494</phone>
    <email>trhoda@luc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Labuszewski, Pharm.D.</last_name>
      <phone>708-216-2307</phone>
      <email>llabuszewski@lumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Rhoda, MPH</last_name>
      <phone>708-216-5494</phone>
      <email>trhoda@luc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Pinzur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346.</citation>
    <PMID>22619242</PMID>
  </reference>
  <reference>
    <citation>Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012 Feb 1;54(3):393-407. doi: 10.1093/cid/cir842. Epub 2011 Dec 12. Review.</citation>
    <PMID>22157324</PMID>
  </reference>
  <reference>
    <citation>Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005 May;9(3):127-38. Review.</citation>
    <PMID>15840453</PMID>
  </reference>
  <reference>
    <citation>Bouazza N, Pestre V, Jullien V, Curis E, Urien S, Salmon D, Tréluyer JM. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br J Clin Pharmacol. 2012 Dec;74(6):971-7. doi: 10.1111/j.1365-2125.2012.04292.x.</citation>
    <PMID>22486719</PMID>
  </reference>
  <reference>
    <citation>Wukich DK, Armstrong DG, Attinger CE, Boulton AJ, Burns PR, Frykberg RG, Hellman R, Kim PJ, Lipsky BA, Pile JC, Pinzur MS, Siminerio L. Inpatient management of diabetic foot disorders: a clinical guide. Diabetes Care. 2013 Sep;36(9):2862-71. doi: 10.2337/dc12-2712. Review.</citation>
    <PMID>23970716</PMID>
  </reference>
  <reference>
    <citation>Pinzur MS, Gil J, Belmares J. Treatment of osteomyelitis in charcot foot with single-stage resection of infection, correction of deformity, and maintenance with ring fixation. Foot Ankle Int. 2012 Dec;33(12):1069-74. doi: DOI: 10.3113/FAI.2012.1069.</citation>
    <PMID>23199855</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Michael Pinzur, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Osteomyelitis</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Foot Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Osteomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>May 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

